Affinage

JMJD1C

Jumonji domain-containing protein 1C · UniProt Q15652

Length
2540 aa
Mass
284.5 kDa
Annotated
2026-06-10
53 papers in source corpus 23 papers cited in narrative 23 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

JMJD1C is a JmjC-domain histone demethylase that erases mono- and di-methyl marks from histone H3K9 (H3K9me1/2) to convert repressive chromatin into a transcriptionally permissive state at target promoters (PMID:20530532). Beyond chromatin, it also demethylates non-histone substrates: it removes methylation from MDC1 at Lys45 to promote MDC1-RNF8 interaction, RNF8-dependent ubiquitylation, and recruitment of the RAP80-BRCA1 complex to DNA double-strand breaks, with JMJD1C itself stabilized by RNF8 and required for radiation/PARP-inhibitor sensitivity (PMID:24240613), and it demethylates STAT3 at Lys140 to permit STAT3-Ptpn6 association and limit STAT3 phosphorylation (PMID:35995859). As a transcriptional coactivator JMJD1C is recruited to promoters by sequence-specific and complex partners — RUNX1-RUNX1T1 (PMID:26494788), HOXA9 (PMID:26878175), USF-1 (PMID:32034158), and the WHISTLE/SF-1 complex (PMID:20530532) — where it lowers H3K9me2 to activate target programs. Its activity is gated by post-translational control: mTOR phosphorylates JMJD1C at T505 in response to feeding/insulin to enable USF-1 binding and lipogenic gene activation (PMID:32034158), while Deltex2-mediated monoubiquitination inhibits its demethylase activity to restrain myogenic differentiation (PMID:28351977). Through these activities JMJD1C governs leukemia stem-cell self-renewal in MLL-AF9/HOXA9 and RUNX1-RUNX1T1 AML (PMID:26494788, PMID:26878175), lipogenesis and adipogenesis (PMID:32034158, PMID:28501567), spermatogonial maintenance (PMID:24006281), stem-cell identity (PMID:24318875, PMID:28826851), and immune-cell fitness including B-cell differentiation and Treg function (PMID:35995859, PMID:38356061, PMID:42095895). A de novo JMJD1C mutation associated with Rett-like neurodevelopmental disease shows mislocalization, reduced MDC1 demethylation, and impaired MECP2 binding (PMID:26181491).

Mechanistic history

Synthesis pass · year-by-year structured walk · 23 steps
  1. 2007 Medium

    Established the first physical link between JMJD1C and a sequence-specific transcription factor, framing it as a nuclear nuclear-receptor coactivator before its enzymatic activity was defined.

    Evidence Yeast two-hybrid, GST pull-down, mammalian one-hybrid, and immunofluorescence of a JMJD1C splice variant (s-JMJD1C) with AR

    PMID:17353003

    Open questions at the time
    • Catalytic activity of the s-JMJD1C variant was not demonstrated
    • Endogenous AR-JMJD1C function in cells not tested
  2. 2010 High

    Defined JMJD1C's core enzymatic identity as an H3K9me1/2 demethylase and showed it operates within a transcription-activating chromatin complex at a steroidogenic promoter.

    Evidence TAP purification, in vitro histone demethylation assay, ChIP and reporter assays in mouse testis context (WHISTLE/SF-1/HSP90α)

    PMID:20530532

    Open questions at the time
    • Genome-wide target spectrum not mapped
    • In vivo requirement for steroidogenesis not tested
  3. 2013 High

    Revealed that JMJD1C acts on a non-histone substrate (MDC1 Lys45) to drive the RAP80-BRCA1 branch of the DNA damage response, expanding its mechanism beyond chromatin and linking it to therapy sensitivity.

    Evidence In vitro demethylation assay, reciprocal Co-IP, laser micro-irradiation, shRNA with ubiquitylation/foci/radiation-sensitivity readouts

    PMID:24240613

    Open questions at the time
    • Demethylase regulation at DSBs vs. promoters not distinguished
    • Structural basis of MDC1 substrate recognition unknown
  4. 2013 Medium

    Extended JMJD1C function to stem-cell maintenance, showing promoter-level H3K9 demethylation sustains a miRNA (miR-302) program that suppresses neural differentiation.

    Evidence ChIP, stable shRNA knockdown, miR-302 mimic rescue, signaling pathway analysis in hESCs

    PMID:24318875

    Open questions at the time
    • Direct vs. indirect control of miR-302 not fully resolved
    • Single lab
  5. 2013 Medium

    Demonstrated an in vivo physiological requirement for JMJD1C in long-term male germ-cell maintenance.

    Evidence Jmjd1c knockout mouse, immunohistochemistry, flow cytometry, apoptosis assays

    PMID:24006281

    Open questions at the time
    • Direct substrates in spermatogonia not identified
    • Cell-autonomous vs. niche effects unresolved
  6. 2015 High

    Positioned JMJD1C as an oncogenic coactivator in AML, directly recruited by the RUNX1-RUNX1T1 fusion to maintain low H3K9me2 at target genes and drive leukemic proliferation in vivo.

    Evidence ChIP-seq, Co-IP, shRNA knockdown, JMJD1C knockout mouse

    PMID:26494788

    Open questions at the time
    • Whether demethylase catalysis is strictly required not dissected here
    • Selectivity over normal hematopoiesis only partly addressed
  7. 2015 Medium

    Connected JMJD1C to neurodevelopmental disease by showing a Rett-associated de novo mutant has reduced MDC1 demethylation, altered localization, and impaired MECP2 binding.

    Evidence Patient mutant functional analysis, in vitro demethylation assay, immunofluorescence, Co-IP, neuronal knockdown

    PMID:26181491

    Open questions at the time
    • Single patient/limited sample size
    • Causality for the clinical phenotype not established genetically
  8. 2016 High

    Showed JMJD1C is selectively required for leukemia stem-cell self-renewal via direct HOXA9 interaction, with minimal effect on normal HSCs — establishing a therapeutic window.

    Evidence In vivo shRNA screen, conditional knockout mice, Co-IP, gene expression analysis in MLL-AF9/HOXA9 models

    PMID:26878175

    Open questions at the time
    • Whether HOXA9 recruitment depends on catalytic activity not resolved
    • Mechanism of LSC vs. HSC differential dependence unclear
  9. 2016 Low

    Implicated JMJD1C protein interactions (MDC1, HSP90) in distinct spermatogenic stages and linked its loss to altered H4K16 acetylation and Oct4 levels.

    Evidence Gene-trap knockout mouse, immunostaining, Co-IP

    PMID:27649575

    Open questions at the time
    • Single Co-IP interactions without reciprocal validation
    • H4K16ac link is correlative, not mechanistic
  10. 2017 High

    Identified post-translational restraint of JMJD1C activity: Deltex2-mediated monoubiquitination inhibits demethylation, controlling H3K9me2 at the MyoD locus during myogenesis.

    Evidence In vitro demethylation assay, mutagenesis of the ubiquitination site, Co-IP, Deltex2 knockout mice, ChIP, shRNA

    PMID:28351977

    Open questions at the time
    • Deltex2 deubiquitinase counterpart not identified
    • Whether other contexts use this regulation unknown
  11. 2017 Medium

    Broadened JMJD1C's stem-cell role to mouse ESC identity, acting through miR-200 and miR-290/295 (with KLF4) to suppress ERK/MAPK and EMT.

    Evidence shRNA knockdown, ERK/MAPK inhibitor rescue, miRNA expression and epistasis analysis

    PMID:28826851

    Open questions at the time
    • Link between JMJD1C and miRNA loci is indirect
    • Single lab
  12. 2017 Medium

    Established a metabolic role in adipogenesis, with JMJD1C controlling H3K9me2 at C/EBP and PPARγ promoters and mitotic clonal expansion.

    Evidence shRNA knockdown in 3T3-L1, ChIP for H3K9me2, triglyceride and uptake assays

    PMID:28501567

    Open questions at the time
    • Single cell-line model
    • Direct promoter occupancy vs. indirect effect not fully separated
  13. 2018 Low

    Extended H3K9me2-dependent target regulation to ATF2 in colorectal cancer migration/invasion.

    Evidence shRNA knockdown, ChIP for H3K9me2/me1, ATF2 overexpression rescue, migration/invasion assays

    PMID:29888107

    Open questions at the time
    • Direct vs. indirect ATF2 regulation not resolved
    • Single lab
  14. 2019 Medium

    Genetically defined the JmjC and zinc-finger domains as essential for leukemia survival and surfaced IL-3/RAS-MAPK/JAK-STAT signaling as a resistance route, with H3K36me marking JMJD1C activity.

    Evidence CRISPR/Cas9 negative-selection screen, domain-specific sgRNAs, scRNA-seq, ChIP for H3K36me, in vivo transplantation

    PMID:31076406

    Open questions at the time
    • Biochemical basis of JmjC-H3K36me relationship needs validation
    • Whether H3K36me is a direct substrate unconfirmed here
  15. 2020 High

    Identified a signal-responsive activation switch: mTOR phosphorylates JMJD1C at T505 upon feeding/insulin to enable USF-1 binding and lipogenic gene activation, linking nutrient sensing to chromatin output.

    Evidence In vitro kinase assay, T505 mutagenesis, Co-IP, ChIP, mouse liver overexpression/knockdown

    PMID:32034158

    Open questions at the time
    • Phosphatase reversing T505 not identified
    • Structural consequence of phosphorylation on USF-1 binding unknown
  16. 2020 Low

    Implicated JMJD1C in cardiomyocyte hypertrophy through repression of Camkk2 and downstream AMPK signaling.

    Evidence shRNA/overexpression, CAMKK2 inhibitor and AMPK knockdown epistasis, cell-size measurement

    PMID:32625104

    Open questions at the time
    • Link from JMJD1C to Camkk2 transcription is indirect
    • Single lab, limited orthogonality
  17. 2022 High

    Showed JMJD1C demethylates STAT3 at Lys140 to enable STAT3-Ptpn6 interaction, restraining STAT3 activity and plasma-cell differentiation — a second defined non-histone substrate.

    Evidence Conditional knockout mice, in vitro demethylation assay, K140R mutagenesis, Co-IP, flow cytometry

    PMID:35995859

    Open questions at the time
    • Direct methyltransferase placing STAT3 K140me not identified
    • Generalization beyond B cells not addressed here
  18. 2022 Low

    Linked JMJD1C to lipid-synthesis gene regulation in MLL-rearranged AML and identified FABP5 as a JmjC-domain-binding partner that feeds back on JMJD1C expression.

    Evidence Mass spectrometry, Co-IP, domain mapping, shRNA with lipidomics

    PMID:35468015

    Open questions at the time
    • Single Co-IP/MS without reciprocal validation
    • How FABP5 binding alters catalytic activity uncharacterized
  19. 2024 Medium

    Dissected demethylase-dependent (AKT, H3K9me2) versus demethylase-independent (STAT3) contributions of JMJD1C to Treg fitness and validated an oral inhibitor that destabilizes intratumoral Tregs.

    Evidence T-cell-specific conditional knockout, ChIP for H3K9me2, AKT/STAT3 analysis, flow cytometry, small-molecule inhibitor

    PMID:38356061

    Open questions at the time
    • Specific STAT3 substrate site in Tregs not identified
    • Selectivity/off-target profile of inhibitor not detailed
  20. 2024 Medium

    Implicated JMJD1C loss in B-cell hyperactivation and autoantibody production (HIT) via increased H3K36me1 at start sites of BCR/NF-κB/cell-cycle genes, nominating H3K36me1 as a substrate mark.

    Evidence Conditional B-cell knockout, RNA-seq, CUT&Tag for H3K36me1, human HIT patient transcriptomics

    PMID:42095895

    Open questions at the time
    • Direct H3K36me1 demethylation by JMJD1C not biochemically shown
    • Relationship between H3K9 and H3K36 substrate activities unresolved
  21. 2024 Low

    Extended H3K9-demethylase-dependent transcriptional control to macrophage PCSK9 and foam-cell formation in atherosclerosis.

    Evidence ChIP for H3K9 methylation, shRNA knockdown, PCSK9 rescue, mouse atherosclerosis model

    PMID:39511107

    Open questions at the time
    • Direct PCSK9 promoter occupancy vs. indirect effect not resolved
    • Single lab
  22. 2025 Low

    Proposed a KLF15-driven, super-enhancer-controlled Jmjd1c/Socs3/JAK-STAT3 axis in neuropathic pain.

    Evidence Dual-luciferase reporter, ChIP-seq, RNA-seq, rat neuropathic pain model, ChIP at Socs3 promoter

    PMID:40485981

    Open questions at the time
    • Pathway not biochemically reconstituted
    • Single lab, limited mechanistic depth
  23. 2026 Medium

    Defined an endothelial Jmjd1c-Srebf2 axis controlling cholesterol biosynthesis and pathological neovascularization via H3K9me2 at the Srebf2 locus.

    Evidence Endothelial-specific knockout, ChIP-qPCR for H3K9me2, RNA-seq, angiogenesis and OIR/CNV models

    PMID:41548765

    Open questions at the time
    • Direct vs. indirect Srebf2 promoter regulation not fully resolved
    • Upstream signal recruiting JMJD1C to Srebf2 unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how JMJD1C's distinct substrate activities (H3K9me1/2, H3K36me, and non-histone targets MDC1 and STAT3) are partitioned across cellular contexts, and what structural and recruitment determinants direct it between DNA-repair, chromatin-activation, and signaling roles.
  • No structural model of substrate selection
  • Methyltransferases generating the non-histone methyl marks unidentified
  • Rules governing histone vs. non-histone substrate choice unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 4 GO:0016491 oxidoreductase activity 3 GO:0140097 catalytic activity, acting on DNA 3 GO:0042393 histone binding 2 GO:0140096 catalytic activity, acting on a protein 2
Localization
GO:0005634 nucleus 2 GO:0000228 nuclear chromosome 1
Pathway
R-HSA-1266738 Developmental Biology 4 R-HSA-168256 Immune System 3 R-HSA-4839726 Chromatin organization 3 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-1430728 Metabolism 2 R-HSA-73894 DNA Repair 1
Partners
FABP5HOXA9MDC1MECP2RNF8RUNX1-RUNX1T1STAT3USF-1

Evidence

Reading pass · 23 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2013 JMJD1C demethylates MDC1 at Lys45, promoting MDC1-RNF8 interaction, RNF8-dependent MDC1 ubiquitylation, and recruitment of the RAP80-BRCA1 complex to DNA double-strand break sites. JMJD1C is stabilized by interaction with RNF8 and is recruited to DSBs, and is required for local ubiquitylations and RAP80-BRCA1 recruitment but not 53BP1 recruitment. JMJD1C depletion caused resistance to ionizing radiation and PARP inhibitors. Co-immunoprecipitation, in vitro demethylation assay, laser micro-irradiation/live-cell imaging, shRNA knockdown with functional readouts (ubiquitylation, foci formation, radiation sensitivity) Nature structural & molecular biology High 24240613
2010 JMJD1C specifically demethylates histone H3K9 mono- and di-methylation and mediates transcriptional activation. JMJD1C was identified as a component of WHISTLE-interacting protein complexes (also containing HSP90α) and replaces WHISTLE at the p450c17 promoter to activate steroidogenesis gene expression via SF-1-mediated interactions during mouse testis development. Immunoaffinity TAP purification, in vitro histone demethylation assay, chromatin immunoprecipitation (ChIP), reporter assays Nucleic acids research High 20530532
2015 JMJD1C functions as a transcriptional coactivator for RUNX1-RUNX1T1 (AML1-ETO) in acute myeloid leukemia; it is directly recruited to RUNX1-RUNX1T1 target genes and regulates their expression by maintaining low H3K9me2 levels. JMJD1C is also required for RUNX1-RUNX1T1-driven proliferation in vivo in knockout mice. ChIP-seq, Co-immunoprecipitation, shRNA knockdown, JMJD1C knockout mouse model Genes & development High 26494788
2016 JMJD1C directly interacts with HOXA9 and modulates a HOXA9-controlled gene-expression program required for MLL-AF9 and HOXA9-driven leukemia stem cell self-renewal. Conditional knockout of JMJD1C substantially decreased LSC frequency and caused differentiation, while only minor defects were observed in normal hematopoietic stem cells. In vivo shRNA screen, conditional JMJD1C knockout mice, Co-immunoprecipitation, gene expression analysis The Journal of clinical investigation High 26878175
2020 JMJD1C is phosphorylated at T505 by mTOR complex in response to feeding/insulin, allowing direct interaction with USF-1 and recruitment to lipogenic gene promoters. JMJD1C demethylates H3K9me2 at these promoters to allow transcriptional activation of lipogenic genes (fatty acid synthase, glycerol-3-phosphate acyltransferase), promoting hepatic and plasma triglyceride synthesis. In vitro kinase assay, Co-immunoprecipitation, ChIP, site-directed mutagenesis of T505, mouse liver overexpression/knockdown models Nature communications High 32034158
2022 Jmjd1c demethylates STAT3 at Lys140 (a non-histone substrate) in B cells to restrain plasma cell differentiation. STAT3 Lys140 hypermethylation caused by Jmjd1c deletion inhibits the interaction of STAT3 with phosphatase Ptpn6, resulting in abnormally sustained STAT3 phosphorylation and activity that promotes plasma cell generation. STAT3 Lys140Arg point mutation completely abrogated the effect of Jmjd1c loss. Conditional knockout mice, in vitro demethylation assay, site-directed mutagenesis (K140R), Co-immunoprecipitation, flow cytometry Nature immunology High 35995859
2017 Deltex2 directly inhibits Jmjd1c demethylase activity by promoting Jmjd1c monoubiquitination; mutation of the monoubiquitination site in Jmjd1c abolishes this inhibitory effect. Jmjd1c activity is required for MyoD expression in vivo and in vitro through removal of H3K9me2 at the MyoD locus. Deltex2 and Jmjd1c act in an epistatic relationship to regulate myogenic differentiation. In vitro demethylation assay, site-directed mutagenesis of ubiquitination site, Co-immunoprecipitation, Deltex2 knockout mice, ChIP, shRNA knockdown Proceedings of the National Academy of Sciences of the United States of America High 28351977
2007 A novel splice variant of JMJD1C (s-JMJD1C) was identified as a coactivator of the androgen receptor (AR). The interaction with AR was established by yeast two-hybrid screening using AR residues 325-919 as bait, confirmed by GST pull-down and mammalian one-hybrid assays. s-JMJD1C localizes to the nucleus. Yeast two-hybrid screen, GST pull-down, mammalian one-hybrid assay, RACE-PCR, immunofluorescence Archives of biochemistry and biophysics Medium 17353003
2013 JMJD1C is expressed in hESCs, binds to the miR-302 promoter, and reduces H3K9 methylation at that locus, thereby maintaining miR-302 expression to inhibit neural differentiation. JMJD1C knockdown reduces miR-302 expression, decreases BMP signaling, enhances TGFβ signaling, and enables neural differentiation upon bFGF withdrawal. ChIP assay, shRNA stable knockdown, miR-302 mimic rescue experiment, signaling pathway analysis The Journal of biological chemistry Medium 24318875
2013 JMJD1C is required for long-term maintenance of male germ cells in mice. Jmjd1c-deficient males became progressively infertile due to reduction of germ cells after 3 months; JMJD1C is most abundantly expressed in undifferentiated spermatogonia, and its loss leads to age-dependent decreases in ZBTB16-positive spermatogonia and increases in apoptotic germ cells. Jmjd1c knockout mouse model, immunohistochemistry, flow cytometry, apoptosis assays Biology of reproduction Medium 24006281
2015 A Rett syndrome-associated de novo JMJD1C mutant shows abnormal subcellular localization, diminished demethylase activity toward MDC1, and reduced binding to MECP2. JMJD1C depletion in neurons compromises dendritic activity. Functional mutant analysis, in vitro demethylation assay, immunofluorescence localization, Co-immunoprecipitation, neuronal knockdown with morphological readout Genetics in medicine Medium 26181491
2017 JMJD1C maintains mouse embryonic stem cell identity at least in part by regulating expression of the miR-200 family and miR-290/295 cluster (with help from KLF4) to suppress ERK/MAPK signaling and epithelial-to-mesenchymal transition. Jmjd1c depletion activates ERK/MAPK signaling and EMT, and ERK/MAPK inhibition rescues the differentiation phenotype. shRNA knockdown, ERK/MAPK inhibitor rescue, microRNA expression analysis, epistasis analysis Stem cell reports Medium 28826851
2017 Jmjd1c depletion in 3T3-L1 cells impairs adipogenesis by interfering with mitotic clonal expansion and by increasing H3K9me2 levels at promoter regions of key adipogenic transcription factors (C/EBPs and PPARγ), reducing their induction and subsequent lipid accumulation and glucose/fatty acid uptake. shRNA knockdown, ChIP assay for H3K9me2 at adipogenic promoters, triglyceride quantification, glucose/fatty acid uptake assays Biochimica et biophysica acta. Molecular basis of disease Medium 28501567
2019 The catalytic Jumonji (JmjC) domain and zinc finger domain of JMJD1C are required for leukemia cell survival in vitro and in vivo, identified by CRISPR/Cas9 negative-selection screening. H3K36 methylation (H3K36me) serves as a marker for JMJD1C activity at gene loci. Loss of the JmjC domain activates RAS/MAPK and JAK-STAT pathways and upregulates IL-3 receptor genes, leading to IL-3 signaling activation as a resistance mechanism. CRISPR/Cas9 negative-selection screen, single-cell RNA-seq, ChIP for H3K36me, domain-specific sgRNAs, in vivo transplantation Blood advances Medium 31076406
2024 JMJD1C is essential for tumor regulatory T (Treg) cell fitness: JMJD1C deletion in Treg cells enhances AKT signals in an H3K9me2 demethylase-dependent manner and enhances STAT3 signals independently of H3K9me2 demethylase activity, leading to robust interferon-γ production and Treg cell fragility in the tumor microenvironment. An oral JMJD1C inhibitor was developed that suppresses tumor growth by targeting intratumoral Treg cells. Conditional T-cell-specific JMJD1C knockout, ChIP for H3K9me2, AKT/STAT3 signaling analysis, flow cytometry, small-molecule inhibitor Nature immunology Medium 38356061
2016 JMJD1C exhibits multiple functions during spermatogenesis and interacts with partner proteins including MDC1 and HSP90; loss of JMJD1C leads to decreased histone H4K16 acetylation in spermatids (required for chromatin remodeling onset) and reduced Oct4 expression in spermatogonia, suggesting roles in spermatid maturation and spermatogonial stem cell self-renewal. Gene-trap knockout mouse model, immunostaining for H4K16ac, Co-immunoprecipitation with MDC1 and HSP90, Oct4 expression analysis PloS one Low 27649575
2018 JMJD1C knockdown in colorectal cancer cells regulates ATF2 expression by modulating H3K9me2 (but not H3K9me1) activity at the ATF2 locus, and overexpression of ATF2 reverses the impaired migration and invasion caused by JMJD1C knockdown. shRNA knockdown, ChIP for H3K9me2/me1, rescue by ATF2 overexpression, in vitro migration/invasion assays American journal of cancer research Low 29888107
2020 JMJD1C regulates CAMKK2-AMPK signaling in cardiomyocytes: JMJD1C overexpression represses Camkk2 expression (but not LKB1), and pharmacological inhibition of CAMKK2 blocks the hypertrophic effects of JMJD1C. AMPK knockdown blocks the inhibitory effects of JMJD1C knockdown on Ang II-induced hypertrophy. shRNA knockdown, gene overexpression, CAMKK2 inhibitor (STO609), AMPK knockdown epistasis, cardiomyocyte size measurement Frontiers in physiology Low 32625104
2022 JMJD1C regulates lipid synthesis genes (FADS2, SCD) in MLL-rearranged AML; FABP5 was identified as a specific interacting protein of JMJD1C that binds its jumonji domain and also regulates JMJD1C mRNA and protein expression. Mass spectrometry for interacting proteins, Co-immunoprecipitation, domain mapping, shRNA knockdown with lipidomics Leukemia & lymphoma Low 35468015
2024 JMJD1C promotes PCSK9 transcription in macrophages through H3K9 demethylation at the PCSK9 locus, promoting foam cell formation; JMJD1C knockdown reduced PCSK9 expression and attenuated atherosclerosis in vivo. ChIP assay for H3K9 methylation at PCSK9 promoter, shRNA knockdown, PCSK9 overexpression rescue, mouse atherosclerosis model Journal of physiology and biochemistry Low 39511107
2024 JMJD1C deficiency in B cells increases H3K36me1 modification at gene start sites of BCR signaling, NF-κB, cell cycle, and SLE-associated pathways, leading to B-cell hyperactivation and production of self-reactive antibodies including PF4/heparin-specific platelet-activating antibodies characteristic of heparin-induced thrombocytopenia. Conditional B-cell JMJD1C knockout, RNA-seq, CUT&Tag for H3K36me1, B-cell functional assays, human HIT patient B-cell transcriptomics Blood Medium 42095895
2026 Endothelial-specific deletion of Jmjd1c suppresses Srebf2 transcription by increasing repressive H3K9me2 marks at the Srebf2 locus in endothelial cells, thereby reducing cholesterol biosynthesis and pathological ocular neovascularization. JMJD1C acts as a key regulator of the Jmjd1c-Srebf2 regulatory axis in endothelial cells. Endothelial-specific Jmjd1c knockout, ChIP-qPCR for H3K9me2, RNA-seq, in vitro angiogenesis assays, in vivo OIR and CNV models Free radical biology & medicine Medium 41548765
2025 Jmjd1c positively regulates Socs3 expression by increasing H3K9 demethylation activity at the Socs3 promoter; the Jmjd1c/Socs3/JAK/STAT3 pathway was validated as downstream in neuropathic pain. KLF15 was shown to activate Jmjd1c transcription by binding to a super-enhancer of Jmjd1c. Dual-luciferase reporter assay, ChIP-seq, RNA-seq, rat neuropathic pain model, ChIP for H3K9 demethylation at Socs3 promoter, gain/loss-of-function experiments Genes & diseases Low 40485981

Source papers

Stage 0 corpus · 53 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2013 JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1-mediated chromatin response to DNA breaks. Nature structural & molecular biology 86 24240613
2015 JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors. Genes & development 74 26494788
2016 MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C. The Journal of clinical investigation 72 26878175
2014 shRNA screening identifies JMJD1C as being required for leukemia maintenance. Blood 69 24501218
2010 Regulation of mouse steroidogenesis by WHISTLE and JMJD1C through histone methylation balance. Nucleic acids research 67 20530532
2007 Identification and characterization of the TRIP8 and REEP3 genes on chromosome 10q21.3 as novel candidate genes for autism. European journal of human genetics : EJHG 62 17290275
2020 Histone demethylase JMJD1C is phosphorylated by mTOR to activate de novo lipogenesis. Nature communications 61 32034158
2013 JMJD1C, a JmjC domain-containing protein, is required for long-term maintenance of male germ cells in mice. Biology of reproduction 59 24006281
2007 A novel variant of the putative demethylase gene, s-JMJD1C, is a coactivator of the AR. Archives of biochemistry and biophysics 56 17353003
2003 Identification and characterization of TRIP8 gene in silico. International journal of molecular medicine 52 14533015
2022 Jmjd1c demethylates STAT3 to restrain plasma cell differentiation and rheumatoid arthritis. Nature immunology 47 35995859
2021 Histone demethylase JMJD1C promotes the polarization of M1 macrophages to prevent glioma by upregulating miR-302a. Clinical and translational medicine 45 34586733
2013 Epigenetic regulation of miR-302 by JMJD1C inhibits neural differentiation of human embryonic stem cells. The Journal of biological chemistry 43 24318875
2015 Mutations in JMJD1C are involved in Rett syndrome and intellectual disability. Genetics in medicine : official journal of the American College of Medical Genetics 42 26181491
2019 JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis. Leukemia 39 30622285
2024 Targeting JMJD1C to selectively disrupt tumor Treg cell fitness enhances antitumor immunity. Nature immunology 35 38356061
2019 Small molecular modulators of JMJD1C preferentially inhibit growth of leukemia cells. International journal of cancer 35 31271662
2017 Deltex2 represses MyoD expression and inhibits myogenic differentiation by acting as a negative regulator of Jmjd1c. Proceedings of the National Academy of Sciences of the United States of America 34 28351977
2021 Circular RNA circ_0006168 enhances Taxol resistance in esophageal squamous cell carcinoma by regulating miR-194-5p/JMJD1C axis. Cancer cell international 31 34022910
2019 Histone Lys demethylase KDM3C demonstrates anti-inflammatory effects by suppressing NF-κB signaling and osteoclastogenesis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 28 31251083
2018 Downregulation of histone demethylase JMJD1C inhibits colorectal cancer metastasis through targeting ATF2. American journal of cancer research 28 29888107
2007 Comparative integromics on JMJD1C gene encoding histone demethylase: conserved POU5F1 binding site elucidating mechanism of JMJD1C expression in undifferentiated ES cells and diffuse-type gastric cancer. International journal of oncology 27 17549425
2023 JMJD1C promotes smooth muscle cell proliferation by activating glycolysis in pulmonary arterial hypertension. Cell death discovery 26 36934091
2020 Inhibition of histone demethylase JMJD1C attenuates cardiac hypertrophy and fibrosis induced by angiotensin II. Journal of receptor and signal transduction research 26 32122211
2017 Histone demethylase JMJD1C regulates esophageal cancer proliferation Via YAP1 signaling. American journal of cancer research 26 28123852
2020 The Histone Demethylase JMJD1C Regulates CAMKK2-AMPK Signaling to Participate in Cardiac Hypertrophy. Frontiers in physiology 25 32625104
2019 Critical role of Jumonji domain of JMJD1C in MLL-rearranged leukemia. Blood advances 25 31076406
2017 Depletion of Jmjd1c impairs adipogenesis in murine 3T3-L1 cells. Biochimica et biophysica acta. Molecular basis of disease 25 28501567
2017 JMJD1C Ensures Mouse Embryonic Stem Cell Self-Renewal and Somatic Cell Reprogramming through Controlling MicroRNA Expression. Stem cell reports 19 28826851
2016 Knockdown of JMJD1C, a target gene of hsa-miR-590-3p, inhibits mitochondrial dysfunction and oxidative stress in MPP+-treated MES23.5 and SH-SY5Y cells. Cellular and molecular biology (Noisy-le-Grand, France) 19 27064872
2024 Jia Wei Qingxin Lotus Seed Drink ameliorates epithelial mesenchymal transition injury in diabetic kidney disease via inhibition of JMJD1C/SP1/ZEB1 signaling pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology 16 39541663
2013 A mediator methylation mystery: JMJD1C demethylates MDC1 to regulate DNA repair. Nature structural & molecular biology 15 24304913
2016 JMJD1C Exhibits Multiple Functions in Epigenetic Regulation during Spermatogenesis. PloS one 13 27649575
2024 Epigenetic roles of KDM3B and KDM3C in tumorigenesis and their therapeutic implications. Cell death & disease 12 38926399
2021 AR-negative prostate cancer is vulnerable to loss of JMJD1C demethylase. Proceedings of the National Academy of Sciences of the United States of America 10 34475205
2022 JMJD1C-regulated lipid synthesis contributes to the maintenance of MLL-rearranged acute myeloid leukemia. Leukemia & lymphoma 9 35468015
2020 Modulators of histone demethylase JMJD1C selectively target leukemic stem cells. FEBS open bio 9 33289299
2015 Expression pattern of JMJD1C in oocytes and its impact on early embryonic development. Genetics and molecular research : GMR 9 26782472
2022 Histone demethylase KDM3C regulates the lncRNA GAS5-miR-495-3p-PHF8 axis in cardiac hypertrophy. Annals of the New York Academy of Sciences 8 35777757
2020 Jmjd1c is dispensable for healthy adult hematopoiesis and Jak2V617F-driven myeloproliferative disease initiation in mice. PloS one 7 32017785
2021 JMJD1C knockdown affects myeloid cell lines proliferation, viability, and gemcitabine/carboplatin-sensitivity. Pharmacogenetics and genomics 6 33075016
2020 Jumonji domain containing 1C (JMJD1C) sequence variants in seven patients with autism spectrum disorder, intellectual disability and seizures. European journal of medical genetics 6 31954878
2024 Histone demethylase JMJD1C advances macrophage foam cell formation and atherosclerosis progression by promoting the transcription of PCSK9. Journal of physiology and biochemistry 4 39511107
2024 BRD4 expression and its regulatory interaction with miR-26a-3p, DLG5-AS1, and JMJD1C-AS1 lncRNAs in gastric cancer progression. Discover oncology 3 39152304
2022 JMJD1C Regulates Megakaryopoiesis in In Vitro Models through the Actin Network. Cells 3 36429088
2024 circ_JMJD1C expedites breast cancer progression by regulating miR-182-5p/JMJD1C/SOX4 axis. Cellular and molecular biology (Noisy-le-Grand, France) 2 38650133
2024 The histone demethylase JMJD1C regulates CPS1 expression and promotes the proliferation of paroxysmal nocturnal haemoglobinuria clones through cell metabolic reprogramming. British journal of haematology 2 38650379
2017 Polymorphisms in JMJD1C are associated with pubertal onset in boys and reproductive function in men. Scientific reports 2 29222425
2025 Enhancer profiling uncovers Jmjd1c as an essential suppressor in neuropathic pain by targeting Socs3. Genes & diseases 1 40485981
2026 Endothelial JMJD1C drives pathological ocular neovascularization by activating SREBF2-dependent cholesterol biosynthesis. Free radical biology & medicine 0 41548765
2026 [Jia Wei Qingxin Lotus Seed Drink improves diabetic kidney disease in mice by regulating the KDM3C/SP1 signaling pathway]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 0 42045024
2026 JMJD1C-mediated epigenetic control of autoimmunity and HIT antibody production. Blood 0 42095895
2025 Transcriptomic and network analyses of an alcohol-induced peripheral neuropathy model identify putative role for histone demethylase Jmjd1c. bioRxiv : the preprint server for biology 0 41279904

Missed literature

Know a paper Affinage missed for JMJD1C? Flag it for the maintainers and the community.

No submissions yet.